News | September 01, 2010

New PCI Guidelines Reinforce Importance of FFR

September 1, 2010 – The European Society of Cardiology (ESC) upgraded fractional flow reserve (FFR) to a class I, level of evidence A, the highest class and level possible. The guidelines for FFR-guided treatment were included in the updated Guidelines on Percutaneous Coronary Intervention (PCI) announced Monday at the ESC congress in Stockholm.

The ESC guidelines, which are intended to assist healthcare providers in clinical decision-making, now classify FFR-guided treatment as class I, with level of evidence A. Level of evidence A is the highest level available, requiring the most clinical evidence and is awarded only when data has been derived from multiple randomized clinical trials or meta-analyses. Class I indicates a general agreement that a given treatment or procedure is beneficial, useful and effective.

“The overall aim of the new guidelines for both percutaneous and surgical revascularization has been to shift emphasis from using primarily the anatomical expression of coronary artery disease to guide treatment toward a more patient-oriented perspective, where all aspects of the disease are taken into account. In this context, the physiological impact of coronary lesions and FFR measurements play a central role,” said Stefan James, M.D., associate professor of cardiology at Uppsala University Hospital in Uppsala, Sweden, and a member of the ESC guidelines task force for myocardial revascularization.

Current data show physiological assessment using FFR prior to placement of coronary stents helps physicians better optimize clinical outcomes by determining which specific lesion or lesions are responsible for a patient’s ischemia, a deficiency of blood supply to the heart caused by blood restriction. The recommendations supported by a level of evidence A state that FFR measurements can be useful in assessing whether an intervention in a coronary lesion is necessary as an alternative to noninvasive functional testing and to help assess intermediate stenosis in patients with anginal symptoms.
Supporting this change are the very strong one- and two-year data from the landmark FAME (Fractional Flow Reserve [FFR] vs. Angiography in Multivessel Evaluation) trial. It demonstrated improved outcomes for patients with multivessel coronary artery disease whose treatment was guided by St. Jude Medical FFR measurement systems rather than by angiography alone.

The FAME study was a randomized, prospective, multi-center trial, which enrolled 1,005 patients with multivessel coronary artery disease. It compared outcomes for patients whose treatment was guided by FFR to those whose treatment was guided only by angiography. The 12-month results, published in the January 15, 2009 issue of the New England Journal of Medicine, demonstrated that instances of major adverse cardiovascular events (MACE), such as death, myocardial infarction or repeat revascularization, were reduced by 30 percent for patients whose treatment was guided by FFR rather than by standard angiography alone.

Two-year FAME results presented as a late-breaking trial during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference demonstrated that patients who received FFR-guided treatment continued to experience improved outcomes over time, including a 34 percent risk reduction of death or myocardial infarction (heart attack). FFR-guided treatment was also demonstrated to be cost-saving, with a difference of about $2,000, or 14 percent, between total healthcare costs for the FFR-guided cohort and the group treated by angiography alone. These lower healthcare costs were a result of reduced procedural costs, reduced follow-up costs for major adverse cardiac events and shorter hospital stays.

About Fractional Flow Reserve
FFR is an index determining the functional severity of narrowings in the coronary arteries. FFR specifically identifies which coronary narrowings are responsible for significantly obstructing the flow of blood to a patient's heart muscle and it is used by the interventional cardiologist to direct coronary interventions and assess results for improved treatment outcomes.

For more information: sjm.com

Related Content

The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks FFRangio angiography imaging derived fractional flow reserve (FFR-angio) technology matched the performance of wire-based FFR measurements. #TCT2018

The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks FFRangio angiography imaging derived fractional flow reserve (FFR-angio) technology matched the performance of wire-based FFR measurements.

News | FFR Technologies | October 04, 2018
October 4, 2018 — The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks
SCAI and the European Society of Cardiology recently added iFR to their guidelines.

An illustration of Philip’s iFR technology, showing the iFR pressure readings and a fusion angio image indicating pressure drops in the vessel during wire pull back. SCAI and the European Society of Cardiology recently added iFR to their guidelines.

Feature | FFR Technologies | September 05, 2018 | Dave Fornell, Editor
The use of invasive, pressure wire-based fractional flow reserve (FFR) in the cath lab is now considered the gold sta
European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines
News | FFR Technologies | August 29, 2018
Philips announced that the European Society of Cardiology (ESC) has incorporated instantaneous wave-free ratio (iFR)...
iFR reference numbers posted for new users in the cath lab at Northwestern Medicine's Central DuPage Hospital in Winfield, Ill.
News | FFR Technologies | July 26, 2018
July 26, 2018 — The Society of Cardiac Angiography and Interventions (SCAI) released a focused update expert consensu
CathWorks Receives CPT Code for Non-invasive FFRangio Measurements During PCI
News | FFR Technologies | July 12, 2018
CathWorks announced the approval of a new Current Procedural Terminology (CPT) code 0523T for non-invasive, 3-D...
The ORBITA Trial showed FFR and iFR are good predictors of PCI outcomes. This was a 2018 PCR late-breaker.
News | FFR Technologies | May 29, 2018
May 29, 2018 — The first placebo-controlled trial that looked at how fractional flow reserve (FFR) and instantaneous
FAST Study Demonstrates High Diagnostic Accuracy of CAAS vFFR
Technology | FFR Technologies | May 22, 2018
Pie Medical Imaging announced that clinical data on its CAAS vFFR (Cardiovascular Angiographic Analysis Systems for...
HeartFlow FFRct Analysis Added to ITP Payment Program in the U.K.
News | FFR Technologies | April 25, 2018
HeartFlow Inc. announced that the National Health Service (NHS) England has chosen the HeartFlow FFRct (fractional flow...
Videos | FFR Technologies | March 15, 2018
An economic analysis of the DEFINE-FLAIR study comparing FFR vs. iFR, found a cost savings of nearly $900.
iFR More Cost-Effective Than FFR in PCI Guidance
News | FFR Technologies | March 12, 2018
Philips announced health economic results from the DEFINE FLAIR clinical trial comparing cost-effectiveness between...
Overlay Init